Nuheara IQBuds Max vs Otofonix Groove

The Nuheara IQBuds Max is a budget-priced OTC hearing aid that earns a B grade with a SoundScore of 3.3/5 in our lab testing. Priced at $499, this visible-in-ear device from 2021 ranks #46 of 65 OTC hearing aids tested, placing it in the top 69% of its category. The standout feature of the IQBuds Max is its exceptional music streaming performance, scoring 4.3/5—a strong result that sits 2.38 points above the category average. For users who prioritize audio entertainment alongside hearing assistance, this device delivers notably better streaming fidelity than most OTC alternatives. However, speech performance presents a mixed picture. Speech in quiet scores 2.0/5, falling 0.78 points below the category average. Speech in noise is essentially at par with competitors at 1.5/5, which is above average for the category but low in absolute terms. Own voice comfort also trails the category average by 0.31 points with a score of 2.2/5. Feedback handling scores a solid 3.4/5 in absolute terms, though this falls 1.14 points below the category average. The IQBuds Max is best suited for users who value music and audio streaming quality over speech clarity, particularly those seeking an affordable entry point into amplification. Competing devices in this price range—including the Elehear Beyond (4.34/5) and Apple AirPods Pro 2 (4.04/5)—offer stronger overall sound performance for similar investment.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.